A Randomized Placebo Controlled Phase II Trial of Afatinib (BIBW2992) as Adjuvant Therapy Following Chemoradiation in Patients With Head and Neck Squamous Cell Carcinoma at High Risk of Recurrence

Trial Profile

A Randomized Placebo Controlled Phase II Trial of Afatinib (BIBW2992) as Adjuvant Therapy Following Chemoradiation in Patients With Head and Neck Squamous Cell Carcinoma at High Risk of Recurrence

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Jan 2018

At a glance

  • Drugs Afatinib (Primary)
  • Indications Head and neck cancer; Hypopharyngeal cancer; Orofacial cancer; Oropharyngeal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Dec 2017 Planned End Date changed from 1 Jan 2020 to 1 Dec 2020.
    • 12 Dec 2017 Status changed to active, no longer recruiting.
    • 11 Sep 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top